Literature DB >> 3718925

Evidence that the acetylcholine binding site is not formed by the sequence alpha 127-143 of the acetylcholine receptor.

M Criado, V Sarin, J L Fox, J Lindstrom.   

Abstract

The sequence alpha 127-143 of the alpha subunit of the acetylcholine receptor has been proposed to contain several important features: (1) the acetylcholine binding site, (2) the only N-glycosylation site of the alpha subunit, at asparagine-alpha 141, and (3) two cysteine residues, at alpha 128 and alpha 142, that may participate in a disulfide bond known to be near the binding site. We tested these hypotheses by using antisera to receptor and its subunits and monoclonal antibodies to the synthetic peptide alpha 127-143 cyclized by a disulfide bond between alpha 128 and alpha 142. Antisera to receptor and its alpha subunit were able to immunoprecipitate the iodinated peptide, and this reaction was inhibited by soluble receptor, but not by membrane-bound receptor. alpha-Bungarotoxin did not inhibit antiserum binding to solubilized receptor. Similarly, cholinergic ligands had little or no effect on binding to immobilized receptors of anti-peptide monoclonal antibodies. In addition, these monoclonal antibodies, when bound to the receptor, did not affect toxin binding kinetics. By contrast, preincubation with concanavalin A did inhibit monoclonal antibody binding. Reduction of the receptor significantly decreased the binding of three of the monoclonal antibodies, but subsequent alkylation with N-ethylmaleimide or the affinity labeling reagent bromoacetylcholine had no additional effect on binding. A dithiothreitol concentration about 100-fold higher that the one needed to reduce the disulfide near the acetylcholine binding site was necessary to inhibit monoclonal antibody binding. We conclude that the sequence alpha 127-143 is not fully exposed on the surface when the receptor is in the membrane.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718925     DOI: 10.1021/bi00358a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Primary structure of an agonist binding subunit of the nicotinic acetylcholine receptor from bovine adrenal chromaffin cells.

Authors:  M Criado; L Alamo; A Navarro
Journal:  Neurochem Res       Date:  1992-03       Impact factor: 3.996

2.  Profile of the continuous antigenic regions on the extracellular part of the alpha chain of an acetylcholine receptor.

Authors:  B Mulac-Jericević; J Kurisaki; M Z Atassi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 3.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 4.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

5.  Conformation of acetylcholine bound to the nicotinic acetylcholine receptor.

Authors:  R W Behling; T Yamane; G Navon; L W Jelinski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Profile of the alpha-bungarotoxin-binding regions on the extracellular part of the alpha-chain of Torpedo californica acetylcholine receptor.

Authors:  B Mulac-Jericevic; M Z Atassi
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

7.  Cell cycle-dependent changes in conformation and composition of nucleosomes containing human histone gene sequences.

Authors:  R Sterner; L C Boffa; T A Chen; V G Allfrey
Journal:  Nucleic Acids Res       Date:  1987-06-11       Impact factor: 16.971

8.  Measuring relative acetylcholine receptor agonist binding by selective proton nuclear magnetic resonance relaxation experiments.

Authors:  R W Behling; T Yamane; G Navon; M J Sammon; L W Jelinski
Journal:  Biophys J       Date:  1988-06       Impact factor: 4.033

9.  Mutation causing severe myasthenia reveals functional asymmetry of AChR signature cystine loops in agonist binding and gating.

Authors:  Xin-Ming Shen; Kinji Ohno; Akira Tsujino; Joan M Brengman; Monique Gingold; Steven M Sine; Andrew G Engel
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

10.  Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds.

Authors:  R B Barlow; O Johnson
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.